Results 131 to 140 of about 64,427 (282)

Antiproliferation effect of imatinib mesylate on MCF7, T-47D tumorigenic and MCF 10A nontumorigenic breast cell lines via PDGFR-β, PDGF-BB, c-Kit and SCF genes

Drug Design, Development and Therapy, 2017
Ali Kadivar,1 Behnam Kamalidehghan,1 Hamid Akbari Javar,2 Benyamin Karimi,3 Reihaneh Sedghi,4 Mohamed Ibrahim Noordin1 1Department of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; 2Department of Pharmaceutics, Faculty of ...
Kadivar A, Kamalidehghan B, Akbari Javar H, Karimi B, Sedghi R, MI Noordin   +5 more
doaj  

Osteoporosis in a 60-Year-Old Male With a History of Chronic Myeloid Leukemia Treated With Imatinib Mesylate. [PDF]

Cureus, 2023
Batra J, Ankireddypalli AR, Kanugula AK, Gorle S, Kaur J.   +4 more
europepmc   +1 more source

Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia [PDF]

, 2002
James C. Barton, S. Christopher Jones, Wade C. Lamberth, Michael T. Reymann, Varian C. Scott   +4 more
openalex   +1 more source

The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate [PDF]

, 2018
Purpose: Gastrointestinal stromal tumours (GIST) are mesenchymal neoplasms of the gastrointestinal tract that are unresponsive to standard sarcoma chemotherapy.
Barghouth, G., Dizendorf, E., Goerres, G., Hany, T., Leyvraz, S., Luthi, F., Pestalozzi, B., Schnyder, P., Stupp, R., von Schulthess, G.   +9 more
core  

Correction to: Real‑world imatinib mesylate treatment in patients with chronic myeloid leukemia: The importance of molecular monitoring and the early molecular response. [PDF]

Ann Hematol, 2023
Ferreira APS, Seguro FS, Abdo ARN, Santos FM, Maciel FVR, Nardinelli L, Giorgi RR, Ruiz ARL, Ferreira MPS, Rego EM, Rocha V, Bendit I.   +11 more
europepmc   +1 more source

Kaposi's sarcoma associated with chronic myeloid leukemia and imatinib mesylate therapy. [PDF]

Clin Case Rep, 2022
D'Addona M, Pezzullo L, Giudice V, Serio B, Baldi C, Zeppa P, Selleri C.   +6 more
europepmc   +1 more source

Myelodysplastic subclones in chronic myeloid leukemia: implications for imatinib mesylate therapy [PDF]

, 2002
Stuart L. Goldberg, Ravi A. Madan, Scott D. Rowley, Andrew L. Pecora, Jack W. Hsu, Ramana Tantravahi   +5 more
openalex   +1 more source

Synergistic cytotoxicity effect of the combination of chitosan nanoencapsulated imatinib mesylate and quercetin in BCR-ABL positive K562 cells. [PDF]

Iran J Basic Med Sci, 2023
Kamyabi R, Jahandideh A, Panahi N, Muhammadnejad S.   +3 more
europepmc   +1 more source

Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases [PDF]

, 2003
Kari K. Eklund, Heikki Joensuu
openalex   +1 more source

The host-directed therapeutic imatinib mesylate accelerates immune responses to Mycobacterium marinum infection and limits pathology associated with granulomas. [PDF]

PLoS Pathog, 2023
Cleverley TL, Peddineni S, Guarner J, Cingolani F, Garcia PK, Koehler H, Mocarski ES, Kalman D.   +7 more
europepmc   +1 more source